Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families

More

Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

More

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

More

Latest News

05.08

Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

Read More
05.06

Zynerba Pharmaceuticals Receives Fast Track Designation for Zygelâ„¢ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)

Read More
04.02

Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

Read More
03.11

Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights

Read More